RxDoctor Payments Data

Steven Pounders, MD

Internal Medicine · Dallas, TXNPI 1124073614

Payments from drug & device makers

$33,061in general payments, 2019–2025

Across 755 payments — averaging $43.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$10K
  • Viiv Healthcare Company$8K
  • Janssen Products, LP$3K
  • Theratechnologies Inc.$3K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Merck$1K
  • plus $7K from 50 others

What the payments were for

  • Consulting fees$12,05036%
  • Speaking & faculty fees$5592%
  • Travel & lodging$7342%
  • Food & beverage$19,47659%
  • Education$2411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead188$10,238
Viiv Healthcare Company201$7,566
Janssen Products, LP12$3,057
Theratechnologies Inc.18$3,019
Biohaven Pharmaceuticals, Inc.4$1,301
Merck40$1,251
AbbVie(2 entities)33$751
Johnson & Johnson(2 entities)32$577
Lilly USA, LLC27$542
Supernus Pharmaceuticals, Inc.2$515
Novo Nordisk37$506
Antares Pharma, Inc.16$467
EMD Serono, Inc.11$285
Napo Pharmaceuticals Inc12$250
Janssen Scientific Affairs, LLC5$240
MDD US Operations, LLC4$227
Pfizer12$218
Amgen9$197
GSK10$164
AstraZeneca7$156
Amarin Pharma, Inc.4$155
Axsome Therapeutics, Inc.2$141
Boehringer Ingelheim8$132
Otsuka America Pharmaceutical, Inc.5$122
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$88
Almatica Pharma LLC3$73
Idorsia Pharmaceuticals US Inc4$61
Lundbeck LLC3$60
Neos Therapeutics, LP3$56
Eisai Inc.3$54
Abbott3$50
Aytu Biopharma, Inc.3$49
Esperion Therapeutics, Inc.2$44
Romark Laboratories, LC3$43
Novartis2$34
Kowa Pharmaceuticals America, Inc.2$32
Takeda Pharmaceuticals U.S.A., Inc.1$26
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$26
Pylant Medical1$24
Hologic Sales And Service, LLC1$21
Jazz Pharmaceuticals Inc.1$20
Mayne Pharma Commercial LLC1$19
Hikma Pharmaceuticals USA1$19
Verity Pharmaceuticals Inc.1$18
Paratek Pharmaceuticals, Inc.1$18
Halozyme Inc1$15
Exact Sciences1$15
Metuchen Pharmaceuticals1$15
Promius Pharma LLC1$15
Galderma Laboratories, L.p.1$14
Endo Pharmaceuticals Inc.1$13
Teva Pharmaceuticals USA, Inc.1$13
Adlon Therapeutics L.p.1$13
Biohaven Pharmaceutical Holding Company Ltd.1$12
Medtronic1$12
Arbor Pharmaceuticals, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,061 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$72,523
Medicare patients
136
Services billed
6,784

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SerostimSomatropin30$606,100
BiktarvyBictegrav/Emtricit/Tenofov Ala132$556,162
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf69$415,865
DovatoDolutegravir Sodium/Lamivudine81$252,688
PrezcobixDarunavir/Cobicistat93$248,753
OdefseyEmtricitab/Rilpiviri/Tenof Ala44$178,364
TriumeqAbacavir/Dolutegravir/Lamivudi41$164,217
OzempicSemaglutide82$86,114
DescovyEmtricitabine/Tenofov Alafenam35$75,524
TivicayDolutegravir Sodium28$71,369
CabenuvaCabotegravir/Rilpivirine11$70,098
IsentressRaltegravir Potassium25$65,555
MounjaroTirzepatide38$38,908
JardianceEmpagliflozin41$38,123
TrulicityDulaglutide13$27,917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$10,238$631,686167 claims
EMD Serono, Inc.Serostim$285$606,10030 claims
Viiv Healthcare CompanyDovato, Triumeq, Tivicay, Cabenuva$7,566$558,373161 claims
Janssen Products, LPSymtuza$3,057$415,86569 claims
Johnson & JohnsonPrezcobix$577$248,75393 claims
MerckIsentress, Pifeltro$1,251$86,26437 claims
Novo NordiskOzempic$506$86,11482 claims
Lilly USA, LLCMounjaro, Trulicity$542$66,82551 claims
Boehringer IngelheimJardiance, Tradjenta$132$49,55657 claims
GSKTrelegy Ellipta, Breo Ellipta$164$32,11647 claims
AstraZenecaFarxiga$156$16,56118 claims
PfizerEliquis$218$13,86316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →